Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide

Publication | Closed Access

DOI

Citations

References

2012

Year

Malcolm D. Mason, Xavier Maldonado, Christopher P. Steidle, S. Guérif, Thomas Wiegel, Egbert van der Meulen, Peter B. F. Bergqvist, Vincent Khoo

Clinical Oncology

UrologyOncologyHigh-risk Prostate CancerGenitourinary CancerDegarelix Versus GoserelinProstate Volume ReductionProstatic DiseaseMedicine